TY - JOUR T1 - Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02554-2020 SP - 2002554 AU - Darius Armstrong-James AU - Jonathan Youngs AU - Tihana Bicanic AU - Alireza Abdolrasouli AU - David W. Denning AU - Elizabeth Johnson AU - Varun Mehra AU - Tony Pagliuca AU - Brijesh Patel AU - Johanna Rhodes AU - Silke Schelenz AU - Anand Shah AU - Frank L. van de Veerdonk AU - Paul E. Verweij AU - P. Lewis White AU - Matthew C. Fisher Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/07/09/13993003.02554-2020.abstract N2 - The SARS-CoV-2 (COVID-19) virus causes a wide spectrum of disease in healthy individuals as well as those with common comorbidities [1]. Severe COVID-19 is characterised acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated.Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections. ER -